In addition to potentially impressive results, Martin Landray et al should be commended for quickly building the research infrastructure for RECOVERY. It is only through such high quality clinical trials that we can determine safe and effective treatments bit.ly/2BbGc9a

#RECOVERYtrial #Dexamethasone Pre-print now available. Huge credit to all those #NHS who have made this possible - most of all to the patients, their families and their loved ones. Thank you all. medrxiv.org/content/10.110…

No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in #RECOVERYtrial Read statement ➡️ recoverytrial.net/files/lopinavi…

Thrilled to hear the good news! The Duke-UTSW connection keeps getting stronger. Congrats Eric D. Peterson

Congrats Robert Harrington !

I'm honored to join the Element Science team to help high-risk cardiovascular patients transition from hospital to home. We are building a next-generation digital wearable platform to change the way care is delivered. businesswire.com/news/home/2020…

Element Science is hiring! We are seeking a Senior Clinical Project Manager to join our growing Clinical team. Come help us change the way care is delivered for high-risk cardiovascular patients. app.jobvite.com/m?3WZQhlwS #job

A New Vaccine to Battle Covid-19 | NEJM. I will always feel fortunate to have worked in Dr. Barton Haynes's lab when I was a Duke University School of Medicine student. nejm.org/doi/full/10.10…

Element Science is hiring! We are seeking a Vice President of Clinical Affairs to lead clinical trials/research, clinical operations, and clinical engineering. Join us in 2021 and launch the pivotal trial for our flagship product. app.jobvite.com/m?3ANeplwQ

The RECOVERY Data Monitoring Committee reviewed data on patients randomised to convalescent plasma vs. usual care. The preliminary analysis based on 10,406 randomised patients with 1873 reported deaths shows no significant difference in the primary endpoint of 28-day mortality.

We owe a debt of gratitude to this group, all of the investigators, and all of the patients who are answering clinically meaningful questions in the appropriate way: with randomization. And magnitude of participation noted by Martin Landray is impressive: x.com/martinlandray/…

Only 10 cases of anaphylaxis after administration of a reported 4,041,396 first doses of Moderna COVID-19 vaccine (2.5 cases per million doses administered)

4.8% increase in heart disease deaths is the largest increase since 2012. Remind me of early The New York Times piece by Harlan Krumholz which highlighted that patients may have been delaying necessary care until their condition had worsened. nytimes.com/2020/04/06/wel… jamanetwork.com/journals/jama/…

Honored to join Duke University School of Medicine Board of Visitors after having been a Duke med student, intern, resident, fellow, & faculty member. Mary E. Klotman, MD and Duke Human Vaccine Institute highlighted today progress towards a pan-coronavirus vaccine. Proud to be part of this community nature.com/articles/s4158…

Element Science is proud to work with committed cardiologists and patients who are helping determine the life-saving potential of an innovative technology like the Jewel. businesswire.com/news/home/2022…

News: Element Science, Inc. will be part of the 2023 Scientific Sessions lineup for Late-Breaking & Featured Science. Join us on November 13 when we will share data on the safety and efficacy of the Jewel, a novel Patch Wearable Cardioverter Defibrillator. professional.heart.org/en/meetings/sc…

Enjoyed talking with HealthCare Business News about what Element Science, Inc. is doing to address the problem of sudden cardiac arrest. In two days, the pivotal trial results of our novel wearable defibrillator will be shared at #aha23. dotmed.com/news/story/616…

Congratulations to John Hummel Dr Roxana Mehran Javed Butler and the Jewel IDE Study investigators and patients for demonstrating the safety and effectiveness of the Jewel, a novel patch wearable cardioverter defibrillator. #AHA23 #CardioTwitter

Big day for our patients. Element Science is thrilled to receive regulatory approval in Europe for the Jewel, a first of its kind Patch Wearable Cardioverter Defibrillator. Strong clinical trial results were key to achieving this milestone. businesswire.com/news/home/2024…